• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Presbyopia lenses offer good quality of life

Article

Presbyopia-correcting intraocular lenses (IOLs) provide a more noticeable positive impact on a patient's quality of life than dual optic accommodating IOLs.

Presbyopia-correcting intraocular lenses (IOLs) provide a more noticeable positive impact on a patient's quality of life than dual optic accommodating IOLs, according to Andrea Galvis and Ivan Ossma of the Instituto para Ninos Ciegos y Sordos, Columbia.

They conducted a non-concurrent case series involving four patient groups implanted with multifocal IOLs or dual optic accommodating lenses: Alcon's Acrysof ReSTOR (n=27), AMO's ReZoom (n=28), AMO's Tecnis multifocal (n=34) and Visiogen's Synchrony dual optic accommodating IOL (n=31).

Subjects were matched based on age at time of implant and the absence of ocular co-morbidity. An adapted VF-7 questionnaire was completed by subjects three and six months after the second eye had received the implant and a questionnaire regarding halo and glare sensitivity was also mailed to all subjects.

The preoperative VF-7 scores ranged from 33.4 to 37.5 for all four groups. At six months follow-up, the mean VF-7 scores were 78.4 in the ReSTOR group, 81.7 in the Tecnis group, 71.5 in the ReZoom group and 84.2 in the Synchrony group. Halos occurred most often in the ReZoom group (21%) and least often in the Synchrony group (6.4%).

Glavis and Ossma concluded from their study that presbyopia-correcting lenses offer a better quality of life than dual optic accommodating lenses.

Related Videos
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
© 2024 MJH Life Sciences

All rights reserved.